Dr. Maxwell on the Need to Personalize the Treatment of Breast Cancer

Article

Kara Maxwell, MD, PhD, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, discusses the need to personalize the treatment of breast cancer.

Kara Maxwell, MD, PhD, instructor, medical oncologist, Basser Research Center for BRCA, University of Pennsylvania, discusses the need to personalize the treatment of breast cancer.

Related Videos
Testi
Patrick Buxton, RN, BSN
Cheryl VerStrate on the Pitfalls of Direct-to-Consumer Genetic Tests
Elizabeth Aronson
MPN-Associated Anemia: What Nurses Should Look Out For
Cancer-Related Cognitive Impairment
Charina Toste
Lindsey Lyle
Related Content
breast cancer

Managing Brain Metastases in a Patient With HER+ Breast Cancer

December 4th 2023
Article

Stephanie L. Graff, MD, FACP; Christine McGinn, MSN, APRN, ACNP-BC; and Jeanine Showalter, MSN, APRN, FNP-BC, AOCNP, share how they approach treatment decision-making following a brain metastasis.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

lymphedema

New Management Strategies Seek to Improve Quality of Life for Patients With Lymphedema

November 20th 2023
Article

Melanie Taylor, APRN, and Mark Lin, APRN, share how they optimize strategies in caring for patients with lymphedema.

The Vitals

Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium

January 16th 2023
Podcast

Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

FDA Approves Capivasertib/Fulvestrant for Advanced/Metastatic, HR+, HER2- Breast Cancer

November 16th 2023
Article

The FDA has approved capivasertib plus fulvestrant to treat patients with locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations.

Talking With Young Patients With Breast Cancer

Talking With Young Patients With Breast Cancer About Ovarian Suppression Treatment

November 8th 2023
Article

Balancing quality-of-life concerns with treatment goals is complicated for young patients with hormone-sensitive breast cancers.

© 2023 MJH Life Sciences

All rights reserved.